Sphere Fluidics has revealed its new brand identity at SLAS Europe in Brussels, Belgium.
The company feels the update better reflects its customer-centric approach and showcases its single cell discovery and analysis technology, following a period of growth and programme success.
Sphere Fluidics’ range of novel cell encapsulation products for single cell analysis and isolation are aimed at easing customer workflows to accelerate scientific discovery.
The company’s platform, Cyto-Mine, uses picodroplet microfluidic technology and is capable of screening up to 40 million cells in several hours, while maintaining viability, to greatly increase throughput.
There has been a period of significant expansion over the last twelve months, including a series of new appointments within the senior leadership team, appointment of a new Chairman to the Board of Directors, expansion to new facilities at Granta Park, Cambridge, UK, and the recent announcement of involvement in the EU-funded research programme, 3DSecret.
3DSecret is bringing together multidisciplinary experts to develop technologies to investigate the stochastic patterns behind metastasis at the single-cell level, to predict cancer evolution.
Dr Frank F Craig, CEO, commented: “We’re focused on transforming single cell screening and isolation, working alongside customers to streamline their workflows. The rebrand signifies our ongoing commitment to growth, the strength of our position in the market as specialists in single cell analysis, and as providers of future-proof technology in this field.”
